Original articleIntraocular Pharmacokinetics of Ranibizumab Following a Single Intravitreal Injection in Humans
Section snippets
Patient Selection and Aqueous Humor Sampling
We included patients treated at the Department of Ophthalmology, University of Bonn. Inclusion criteria were planned elective cataract surgery for clinically significant lens opacification and a concurrent macular edema secondary to AMD, diabetic maculopathy, or central or branch RVO in the same eye that had been treated with a single intravitreal injection of 0.5 mg ranibizumab within 40 days before surgery. Patients with any additional intravitreal injections within 6 months before surgery or
Results
We measured aqueous humor concentration of ranibizumab in 18 eyes of 18 patients (mean age 75.1 years; age range 61–85 years; 10 female, 8 male) who had received an intravitreal injection of 0.5 mg of the drug within a period of 1 to 37 days prior to sampling (Figure 2). Macular edema was secondary to neovascular AMD in 9 patients, diabetic maculopathy in 6 patients, and central or branch RVO in 3 patients. The highest drug concentration was measured on the first day after injection (n = 2;
Discussion
Data on the ocular pharmacokinetics of ranibizumab have so far only been available from animal studies. Hence, previous predictions of pharmacokinetic properties of ranibizumab in humans as well as comparisons with other anti-VEGF agents such as bevacizumab and aflibercept had to rely on estimates of ranibizumab half-life values based on either molecular weight or animal data.9, 10, 11 Herein, we quantified ranibizumab concentration in human aqueous humor samples and provided data on the
Tim U. Krohne, MD, is a vitreoretinal specialist at the Department of Ophthalmology of University of Bonn, Germany. After graduating from University of Heidelberg, Germany, he completed his residency in Bonn in 2007. He went on to perform a postdoctoral research fellowship in cell biology at the Scripps Research Institute in La Jolla, California, before joining the faculty of University of Bonn in 2011. His research focuses on retinal cell biology, stem cells, and vitreoretinal diseases.
References (26)
- et al.
The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema
Ophthalmology
(2011) - et al.
Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans
Am J Ophthalmol
(2008) Intravitreal injections: does globe size matter?
J Cataract Refract Surg
(2002)- et al.
Pharmacokinetics of intravitreal bevacizumab (Avastin)
Ophthalmology
(2007) - et al.
Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection
Ophthalmology
(2003) - et al.
Pharmacokinetics of intravitreal ranibizumab (Lucentis)
Ophthalmology
(2007) - et al.
Ranibizumab for neovascular age-related macular degeneration
N Engl J Med
(2006) - et al.
Ranibizumab versus verteporfin for neovascular age-related macular degeneration
N Engl J Med
(2006) - et al.
Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study
Ophthalmology
(2010) - et al.
Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study
Ophthalmology
(2010)
Intraocular pharmacokinetics after a single intravitreal injection of 1.5 mg versus 3.0 mg of bevacizumab in humans
Retina
Predicted biologic activity of intravitreal bevacizumab
Retina
Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye)
Retina
Cited by (206)
Quantitative intravitreal pharmacokinetics in mouse as a step towards inter-species translation
2023, Experimental Eye ResearchFrom in vitro to in vivo: A comprehensive guide to IVIVC development for long-acting therapeutics
2023, Advanced Drug Delivery ReviewsChronic ocular small vessel disease: An overview of diabetic retinopathy and its relationship with cardiovascular health
2023, American Heart Journal Plus: Cardiology Research and PracticeRisk of Intraocular Pressure Increase With Intravitreal Injections of Vascular Endothelial Growth Factor Inhibitors: A Cohort Study
2023, American Journal of Ophthalmology
Tim U. Krohne, MD, is a vitreoretinal specialist at the Department of Ophthalmology of University of Bonn, Germany. After graduating from University of Heidelberg, Germany, he completed his residency in Bonn in 2007. He went on to perform a postdoctoral research fellowship in cell biology at the Scripps Research Institute in La Jolla, California, before joining the faculty of University of Bonn in 2011. His research focuses on retinal cell biology, stem cells, and vitreoretinal diseases.
Carsten H. Meyer, MD, is professor of ophthalmology and a head of department at Klinik Pallas, Olten, Switzerland. He obtained his medical degree from University of Munich, Germany, and completed his residency at University of Lübeck, Germany, before pursuing a 2-year vitreoretinal fellowship at Duke Eye Center, Durham, North Carolina. He joined the University of Bonn, Germany in 2006 and became professor in 2007. His research interests include retinal imaging, chromovitrectomy, and novel therapies for AMD.
Carsten H. Meyer is currently at Klinik Pallas, Olten, Switzerland.